Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients

Table 3

Pearson’s correlation coefficient () between the cumulative dose and treatment duration and the OCT parameters in the study group.

OCT	Cumulative dose in grams	Treatment duration in years
CFT	−0.013; (p value = 0.936)	−0.017; (p value = 0.918)
Parafoveal thickness
Superior	−0.134; (p value = 0.409)	−0.135; (p value = 0.405)
Inferior	−0.048; (p value = 0.770)	−0.048; (p value = 0.768)
Nasal	0.075; (p value = 0.644)	0.074; (p value = 0.649)
Temp.	−0.188; (p value = 0.247)	−0.189; (p value = 0.244)
Perifoveal thickness
Superior	−0.065; (p value = 0.689)	−0.068; (p value = 0.678)
Inferior	−0.259; (p value = 0.107)	−0.260; (p value = 0.105)
Nasal	0.086; (p value = 0.598)	0.084; (p value = 0.605)
Temp.	−0.253; (p value = 0.115)	−0.256; (p value = 0.111)
RNFL	−0.119; (p value = 0.464)	−0.120; (p value = 0.462)
GCC thickness	−0.003; (p value = 0.984)	−0.002; (p value = 0.989)
FLV	0.056; (p value = 0.730)	−0.055; (p value = 0.736)
GLV	0.114; (p value = 0.483)	−0.114; (p value = 0.482)